# Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

Source: https://onco.cc/trials/nct07615101/  
OnCo record `nct07615101` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 68-Ga-NYM032 in prostate cancer, run by Norroy Bioscience Co., LTD, now recruiting.

## Summary

Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. is a phase 3 interventional study registered as NCT07615101 by Norroy Bioscience Co., LTD, with 365 participants planned, started 2026-08-06 and due to reach its primary completion in 2027-06-30. Interventions recorded: 68-Ga-NYM032.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07615101
- Phase: 3
- Setting: Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
- Sponsor: Norroy Bioscience Co., LTD
- Enrolled: 365

## Sources

- ClinicalTrials.gov NCT07615101: https://clinicaltrials.gov/study/NCT07615101

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct07615101.json